Trial Profile
T-Cell Reinfusion After Interfering With Lymphocyte Binding Location of AIDS Virus Through Zinc-finger-nuclease Elimination of CCR5 Receptors: The TRAILBLAZER Study
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 27 Jul 2023
Price :
$35
*
At a glance
- Drugs SB 728 T (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Therapeutic Use
- Acronyms TRAILBLAZER
- 01 Jan 2022 Status changed from recruiting to active, no longer recruiting.
- 22 Jul 2019 Status changed from not yet recruiting to recruiting.
- 17 May 2019 Planned initiation date changed from 30 Apr 2019 to 30 May 2019.